Incidensen af infusionsrelaterede symptomer aftager væsentligt med de følgende infusioner og er under 1% efter 8 doser MabThera.
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1% after eight doses of MabThera.